Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Midatech Pharma Plc - news published 64 - readings 3.316

BACK

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Filed pursuant to Rule 424(b)(3) Registration No.: 333-240984 PROSPECTUS SUPPLEMENT MIDATECH PHARMA PLC 9,888,640 Ordinary Shares Representing 1,977,728 American Depositary Shares This prospectus supplement (the "Prospectus Supplement") amends and supplements our prospectus contained in our Post-Effective Amendment No. 2 to our Registration Statement on Form F-1, eff ...

24.01.2023

Midatech Pharma plc

Result of General Meeting

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 23 January 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 23 January 2023 14:29:15 UTC .

23.01.2023

Midatech Pharma plc

Holding(s) in Company

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 16 January 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 16 January 2023 12:00:03 UTC .

16.01.2023

Midatech Pharma plc

Planned Dose Escalation in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma - Form 6-K

Planned Dose Escalation in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following completion of one month of treatment with MTX-110 in the first patient, its Pha ...

12.01.2023

Midatech Pharma plc

INFORMATION RELATING TO MIDATECH - Form 6-K

INFORMATION RELATING TO MIDATECH Midatech Business Midatech is focused on the research and development of medicines which it believes would benefit from improved bio-delivery and/or bio-distribution using its proprietary drug delivery technologies: · Q-Sphera™ platform: Its disruptive polymer microsphere microtechnology is used for injectables to prolong and control the rel ...

11.01.2023

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

06.01.2023

Midatech Pharma plc

Current Report by Foreign Issuer - Form 6-K

THIS DOCUMENT AND THE ENCLOSED FORM OF PROXY ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document and/or the action you should take, you are recommended to seek your own financial advice immediately by consulting your stockbroker, bank manager, solicitor, accountant or other independent financial adviser duly authorise ...

06.01.2023

Midatech Pharma plc

Shareholder Circular and Notice of General Meeting to be held on 23 January 2023

THIS DOCUMENT AND THE ENCLOSED FORM OF PROXY ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document and/or the action you should take, you are recommended to seek your own ﬁnancial advice immediately by consulting your stockbroker, bank manager, solicitor, accountant or other independent ﬁnancial adviser duly authori ...

06.01.2023

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

19.12.2022

Midatech Pharma plc

Holding(s) in Company

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 19 December 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 19 December 2022 12:28:37 UTC .

19.12.2022

Midatech Pharma plc

Supplemental Prospectus - Form 424B5

Filed pursuant to Rule 424(b)(5) Registration No.: 333-267932 PROSPECTUS SUPPLEMENT (to Prospectus dated October 26, 2022) MIDATECH PHARMA PLC 393,973 American Depositary Shares Representing 9,849,325 Ordinary Shares We are offering 393,973 of our American Depositary Shares, or Depositary Shares, at a price of $1.00 per Depositary Share pursuant to this prospectus supplement, ...

16.12.2022

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

15.12.2022

Midatech Pharma plc

Explanatory Note - Form 6-K

Explanatory Note On December 13, 2022, Midatech Pharma plc (the "Company," "Midatech," "we," "our" or "us") announced it had entered into an arrangement agreement (the "Arrangement Agreement") with Bioasis Technologies Inc., a corporation existing under the laws of British Columbia, Canada ("Bioasis"). Pursu ...

15.12.2022

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 13 December 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 13 December 2022 22:06:23 UTC .

13.12.2022

Midatech Pharma plc

Company to Remain Listed on NASDAQ; Proposed Cancellation of Admission to Trading on AIM - Form 6-K

Company to Remain Listed on NASDAQ; Proposed Cancellation of Admission to Trading on AIM and General Meeting Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that the Company has conditionally agreed to acquire the entire issued and to be issued share ...

13.12.2022

Midatech Pharma Plc - news published 64 - readings 3.316

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Midatech Pharma plc

Result of General Meeting

Midatech Pharma plc

Holding(s) in Company

Midatech Pharma plc

Planned Dose Escalation in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma - Form 6-K

Midatech Pharma plc

INFORMATION RELATING TO MIDATECH - Form 6-K

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Midatech Pharma plc

Current Report by Foreign Issuer - Form 6-K

Midatech Pharma plc

Shareholder Circular and Notice of General Meeting to be held on 23 January 2023

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Midatech Pharma plc

Holding(s) in Company

Midatech Pharma plc

Supplemental Prospectus - Form 424B5

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Midatech Pharma plc

Explanatory Note - Form 6-K

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Midatech Pharma plc

Company to Remain Listed on NASDAQ; Proposed Cancellation of Admission to Trading on AIM - Form 6-K

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member